AT 7519

Drug Profile

AT 7519

Alternative Names: AT7519; AT7519M

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Astex Therapeutics
  • Developer Astex Pharmaceuticals; Astex Therapeutics; Multiple Myeloma Research Consortium; National Cancer Institute (Canada)
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Cyclin-dependent kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Multiple myeloma
  • Phase I Solid tumours

Most Recent Events

  • 01 Apr 2016 Phase-I clinical trials in Solid tumours (Combination therapy, Inoperable/Unresectable, Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT02503709)
  • 11 Aug 2015 Phase-II development is ongoing for Multiple myeloma (Second-line therapy) in USA and Chronic lymphocytic leukaemia in Canada (Astex Pharmaceuticals pipeline, August 2015)
  • 24 Jul 2015 The National Cancer Institute plans a phase I trial (Combination therapy, Metastatic disease) for Solid tumours in USA (NCT02503709)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top